C-RBEERubedo Life Sciences
senescent cells, GPX4 modulation, drug discovery platform
clearingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-RBEE
C-RBEEC-RBEEsenescent cells, GPX4 modulation, drug discovery platform
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Rubedo Life Sciences presents aging as a process driven in part by pathologic cells, especially senescent cells, and states that selectively targeting or eliminating those cells can treat age-related disease and preserve or restore biological youth and health span at the cellular level.
SourceRubedo Life Science’s stated position was that age-related disease is driven in part by pathological, senescent cells and other harmful cellular states, and that medicine should target those root causes rather than only downstream symptoms. The company presented selective elimination of senescent or otherwise pathologic cells, while preserving healthy cells, as a way to rejuvenate tissues, slow or reverse disease progression, and preserve biological youth.
SourceRubedo Life Sciences states that age-related diseases can be treated with customized, targeted therapeutics that extend health-span. The company says its approach uses the ALEMBIC computational drug discovery platform and proprietary chemistry engineering to create novel small-molecule drugs that are selective, safe, and well tolerated, with lead compounds designed to be activated specifically in pathological cells that drive age-related disease.
SourceRubedo Life Sciences states that age-related diseases can be addressed with intelligent drug platforms that produce unique, targeted, and controlled therapies, and that its novel technology can fight aging and promote health span in a smart, safe, and controlled way.
Source